Soon to Be Phase 1 Trial: FX‑111, A Selective ARon Degrader with the Potential to Rethink Androgen Deprivation in Prostate Cancer

A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current therapies often arises as AR levels increase and the receptor mutates or amplifies. Existing drugs mainly target the cytoplasmic, hormone‑unbound AR (ARoff), but FX‑111 flips this strategy by honing in on the nuclear, ligand‑occupied AR that is actually driving gene expression and tumor progression.

FX‑111 is built as a Cereblon‑based heterobifunctional degrader, essentially a small‑molecule PROTAC that links an AR‑binding element to an E3‑ligase recruiter. This design allows it to latch onto the AR once it has bound androgen, exploiting a newly revealed allosteric pocket that opens only in the hormone‑bound state. In preclinical models, the molecule achieves rapid and sustained degradation of AR with a DC₅₀ around 10 nM, far exceeding typical cellular concentrations and suggesting high potency at pharmacologically relevant doses. Crucially, broad proteome‑wide analyses show no detectable degradation of other steroid hormone receptors or off‑target proteins, reinforcing its specificity for ARon.

One of the most striking features of FX‑111 is its non‑competitive behavior with androgens. Unlike classical AR antagonists or orthosteric degraders, which lose potency as intratumoral hormone levels rise, FX‑111 continues to degrade AR even in the presence of elevated androgen or alternative AR agonists. This insensitivity to ligand concentration means the drug remains effective in settings that mimic the high‑androgen microenvironment often seen in advanced lesions or after androgen deprivation therapy. In genetically defined models, FX‑111 also degrades clinically relevant AR mutants, including some that confer resistance to approved AR‑directed agents, broadening its potential utility across heterogeneous mCRPC populations.

Transcriptomic profiling in LNCaP and VCaP prostate cancer cells further underscores its precision. Treatment with FX‑111 completely silences androgen‑driven transcriptional programs, abolishing the changes in gene expression that normally fuel proliferation and survival. In contrast, under hormone‑depleted conditions, FX‑111 exerts only minimal effects on the transcriptome, indicating that its activity is tightly coupled to the presence of active ARon rather than non‑specific toxicity. This clean on‑target signature suggests that the drug may deliver strong pathway suppression without overwhelming collateral gene‑regulatory disruption.

In vivo, FX‑111 demonstrates robust pharmacodynamic and antitumor effects. When administered orally at 10 mg/kg twice daily to VCaP xenograft‑bearing mice, the compound induces pronounced AR degradation, potently suppresses prostate‑specific antigen levels, and significantly inhibits tumor growth. Even when exogenous androgen is added, simulating the kind of intratumoral hormone exposure that typically blunts conventional AR‑targeted therapies, FX‑111 maintains its ability to degrade AR and suppress AR‑dependent transcription. Normal AR‑rich tissues such as the prostate and testes also show strong suppression of AR function, accompanied by organ weight loss, consistent with deep pathway blockade but raising predictable on‑target toxicities that will need careful monitoring in humans.

NOTE: Beyond mCRPC, there is speculation that FX‑111 could work in patients without full systemic androgen deprivation (no need of ADT), since it targets the active ARon state regardless of circulating hormone levels.

The molecule is currently in IND‑enabling studies, with clinical development planned to begin in 2026, positioning it as a potential new pillar in the AR‑targeted arsenal if safety and efficacy translate from preclinical models to patients.

Source.